Illumina, A global genomics leader, provides comprehensive next-generation sequencing (NGS) solutions to the research, clinical, and applied markets. Illumina technology is responsible for generating more than 90% of the world’s sequencing data.1 Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond. By empowering large-scale analysis of genetic variation and function, Illumina is enabling studies that were not imaginable just a few years ago, moving us closer to the realization of precision medicine.
1Data calculations on file. Illumina, Inc., 2015.
Through this program, Illumina offers exclusive rebates to first-time Illumina customers only on the following benchtop sequencing instrumentation to member companies:
|MiSeq®||Allows small genome sequencing and assembly, and enables detection of targeted variants with unmatched accuracy|
|MiSeqDx®*||First FDA cleared IVD platform with a growing menu of assays that enables clinical laboratories to create and deploy NGS based molecular diagnostic testing in their labs|
|MiSeq FGx™||A compact, fully validated NGS platform for forensic genomics applications|
|MiniSeq™||Flexible and affordable system that allows researchers to transition easily between sequencing projects for both DNA and RNA|
*For In Vitro Diagnostic Use Only
|NextSeq®500||Enables rapid sequencing of exomes, targeted panels, and transcriptomes|
|NextSeq®550||Enables NGS and Cytogenetic Array Scanning on one instrument|
For Research Use Only. Not for use in diagnostic procedures.
Eligible Biotech Associations
In addition to members of BIO, members of the following state and regional biotech associations can take advantage of this program: